DIAGNOS Receives Regulatory Approval from the Costa Rica Health Agency for its Artificial Intelligence Enabled Pathology Detection Systems
August 18 2022 - 12:26PM
DIAGNOS Inc. (“
DIAGNOS”, the
“
Corporation” or ”we”) (TSX Venture: ADK) (OTCQB:
DGNOF) a leader in early detection of critical health issues
through the use of its FLAIRE platform based on Artificial
Intelligence (AI), is proud to announce the receipt of approval
from the Costa Rican regulatory agency (Ministerio de Salud) for
its Artificial Intelligence enabled Pathology Detection Systems.
DIAGNOS’ platform has been approved for having
complied with the legal requirements and applicable regulations.
Valid for a period of five years, this approval allows the
immediate commercial deployment of DIAGNOS’ Pathology Detection
Systems in Costa Rica. The registration will be held for DIAGNOS by
Costa Rica based Aselcom, a highly respected local partner
specialized in the sale of medical technologies to hospitals,
medical clinics, and optical stores.
“We were waiting for this approval to begin our
sales to customers who were on hold during the approval process and
to resume our discussions regarding screening programs with the
Government of Costa Rica and,” said Mr. Guillermo Moreno
Robles, VP of Sales of DIAGNOS. “This approval represents
$1,500,000 USD of potential revenues for our company.”
Ocular diseases have become the leading cause of
blindness worldwide in patients between the ages of 20 and 64.
Costa Rica is no different from other countries, with almost 15% of
its population over the age of 20 suffering from diabetes, where
less than 11% of these cases are diagnosed. Of the patients
diagnosed with diabetes, 35% were identified with diabetic
retinopathy, a disease known to severely affect vision.
“We are very grateful to both the Quebec and
Canadian Government for working with us closely on this approval
for our Pathology Detection Systems in Costa Rica,” stated
Mr. Andre Larente, President of
DIAGNOS. “This announcement reflects DIAGNOS’ commitment
to continue to deploy our innovative Pathology Detection technology
using Ocular Images not just in select countries, but
worldwide.”
About DIAGNOSDIAGNOS is a publicly traded
Canadian corporation dedicated to early detection of critical
health problems based on its FLAIRE Artificial Intelligence (AI)
platform. FLAIRE allows for quick modifying and developing of
applications such as CARA (Computer Assisted Retina Analysis).
CARA’s image enhancement algorithms provide sharper, clearer and
easier-to-analyze retinal images. CARA is a cost-effective tool for
real-time screening of large volumes of patients. CARA has been
cleared for commercialization by the following regulators: Health
Canada, the FDA (USA), CE (Europe), COFEPRIS (Mexico) and Saudi FDA
(Saudi Arabia).
Additional information is available at
www.DIAGNOS.com and www.sedar.com
This news release contains forward-looking
information. There can be no assurance that forward-looking
information will prove to be accurate, as actual results and future
events could differ materially from those anticipated in these
statements. DIAGNOS disclaims any intention or obligation to
publicly update or revise any forward-looking information, whether
as a result of new information, future events or otherwise. The
forward-looking information contained in this news release is
expressly qualified by this cautionary statement.
Neither the TSX Venture Exchange nor its
Regulation Services Provider (as that term is defined in the
policies of the TSX Venture Exchange) accepts responsibility for
the adequacy or accuracy of this release.
For further information, please contact:
Mr. André Larente, President
DIAGNOS Inc.
Tel: 450 678-8882, ext. 224
Email: alarente@DIAGNOS.ca
Diagnos (TSXV:ADK)
Historical Stock Chart
From Jun 2024 to Jul 2024
Diagnos (TSXV:ADK)
Historical Stock Chart
From Jul 2023 to Jul 2024